Date: 2011-05-18
Type of information: Fundraising
Company: Themis Bioscience (Austria)
Investors: Crédit Agricole Private Equity (France) - Ventech (France)
Amount: €5 million
Funding type: series A financing round
Planned used: The investment will be used to expedite the pre-clinical and clinical development activities for Themis’lead product candidates, a Dengue and a Chikungunya Fever vaccine. Both vaccine candidates have demonstrated promising preclinical data.They arebased on a novel vaccine vector technology that was initially developed at the Institut Pasteur in Paris, with which Themis collaborates.
Others: Themis Bioscience has announced the closing of a € 5 million series A financing round.
Therapeutic area: Infectious diseases
